Information Provided By:
Fly News Breaks for October 18, 2019
CRL
Oct 18, 2019 | 06:17 EDT
BofA/Merrill analyst Juan Avendano downgraded Charles River to Neutral from Buy with a $150 price target. The company's acquisition growth opportunities "seem less compelling" going forward, Avendano tells investors in a research note. He believes Charles Rivers' roll-up strategy in the drug safety assessment space "appears to have run its course." As such, the analyst views the shares as less compelling.
News For CRL From the Last 2 Days
There are no results for your query CRL